|Title||Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.|
|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Feng X, Zhou CKe, Clish CB, Wilson KM, Pernar CH, Dickerman BA, Loda M, Finn SP, Penney KL, Schmidt DR, Heiden MGVander, Giovannucci EL, Ebot EM, Mucci LA|
|Journal||Cancer Epidemiol Biomarkers Prev|
|Date Published||2021 05|
BACKGROUND: The gene fusion and loss are two of the most common somatic molecular alterations in prostate cancer. Here, we investigated the association of prediagnostic-circulating metabolomics and prostate cancer defined by ERG or PTEN status to improve understanding of these etiologically distinct molecular prostate cancer subtypes.
METHODS: The study was performed among 277 prostate cancer cases with ERG status, 211 with PTEN status, and 294 controls nested in the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS). We profiled 223 polar and non-polar metabolites using LC-MS in prediagnostic plasma specimens. We applied enrichment analysis and multinomial logistic regression models to identify biological metabolite classes and individual metabolites associated with prostate cancer defined by ERG or PTEN status.
RESULTS: Compared with noncancer controls, sphingomyelin (: 0.01), ceramide (: 0.04), and phosphatidylethanolamine (: 0.03) circulating levels were enriched among ERG-positive prostate cancer cases. Sphingomyelins (: 0.02), ceramides (: 0.005), and amino acids (: 0.02) were enriched among tumors exhibiting PTEN-loss; unsaturated diacylglycerols (: 0.003) were enriched among PTEN-intact cases; and unsaturated triacylglycerols were enriched among both PTEN-loss (: 0.001) and PTEN-intact (: 0.0001) cases. Although several individual metabolites identified in the above categories were nominally associated with ERG or PTEN-defined prostate cancer, none remained significant after accounting for multiple testing.
CONCLUSIONS: The molecular process of prostate carcinogenesis may be distinct for men with different metabolomic profiles.
IMPACT: These novel findings provide insights into the metabolic environment for the development of prostate cancer.
|Alternate Journal||Cancer Epidemiol Biomarkers Prev|
|PubMed Central ID||PMC8102317|
|Grant List||K99 CA248335 / CA / NCI NIH HHS / United States |
P50 CA090381 / CA / NCI NIH HHS / United States
KL2 TR002542 / TR / NCATS NIH HHS / United States
U01 CA167552 / CA / NCI NIH HHS / United States
P30 CA006516 / CA / NCI NIH HHS / United States
Massimo Loda, M.D.